Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Selexys Pharmaceuticals Corp.
DescriptionHumanized mAb against P selectin glycoprotein ligand-1 (PSGL-1)
Molecular Target P selectin glycoprotein ligand-1 (PSGL-1) (CD162) (SELPLG)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationCrohn's disease
Indication DetailsTreat Crohn's disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today